The concept of cardiometabolic risk: Bridging the fields of diabetology and cardiology

References

• Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988; 37: 1595–607
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991; 14: 173–94
   PubMed Web of Science ®Google Scholar
• Reaven GM. Pathophysiology of insulin resistance in human disease. Physiol Rev. 1995; 75: 473–86
   PubMed Web of Science ®Google Scholar
• Rader DJ. Effect of insulin resistance, dyslipidemia, and intra-abdominal adiposity on the development of cardiovascular disease and diabetes mellitus. Am J Med. 2007; 120 Suppl 1: S12–8
   Google Scholar
• Bansilal S, Farkouh ME, Fuster V. Role of insulin resistance and hyperglycemia in the development of atherosclerosis. Am J Cardiol. 2007; 99: 6B–14B
   Google Scholar
• Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–97.
   PubMed Web of Science ®Google Scholar
• Wilson PW, D'Agostino RB, Parise H, Sullivan L, Meigs JB. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation. 2005; 112: 3066–72
   PubMed Web of Science ®Google Scholar
• Dekker JM, Girman C, Rhodes T, Nijpels G, Stehouwer CD, Bouter LM, et al. Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study. Circulation. 2005; 112: 666–73
   PubMed Web of Science ®Google Scholar
• McNeill AM, Rosamond WD, Girman CJ, Golden SH, Schmidt MI, East HE, et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care. 2005; 28: 385–90
   PubMed Web of Science ®Google Scholar
• Gami AS, Witt BJ, Howard DE, Erwin PJ, Gami LA, Somers VK, et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol. 2007; 49: 403–14
   PubMed Web of Science ®Google Scholar
• Galassi A, Reynolds K, He J. Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. Am J Med. 2006; 119: 812–9
   PubMed Web of Science ®Google Scholar
• Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2005; 28: 2289–304
   PubMed Web of Science ®Google Scholar
• Gale EA. The myth of the metabolic syndrome. Diabetologia. 2005; 48: 1679–83
   PubMed Web of Science ®Google Scholar
• American College of Endocrinology/American Association of Clinical Endocrinologists: Reaffirmation of the 2003 ACE Insulin Resistance Syndrome (IRS) Position Statement. Available at: http://www.aace.com/pub/pdf/guidelines/IRSStatement.pdf.
   Google Scholar
• Einhorn D, Reaven GM, Cobin RH, Ford E, Ganda OP, Handelsman Y, et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract. 2003; 9: 237–52
   PubMedGoogle Scholar
• Alberti KG, Zimmet P, Shaw J. The metabolic syndrome—a new worldwide definition. Lancet. 2005; 366: 1059–62
   PubMed Web of Science ®Google Scholar
• International Chair on Cardiometabolic Risk. Available at: http://www.cardiometabolic-risk.org/about-the-chair/index.html.
   Google Scholar
• Després JP. Is visceral obesity the cause of the metabolic syndrome?. Ann Med. 2006; 38: 52–63
   PubMed Web of Science ®Google Scholar
• Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005; 112: 2735–52
   PubMed Web of Science ®Google Scholar
• Lemieux I, Pascot A, Couillard C, Lamarche B, Tchernof A, Alméras N, et al. Hypertriglyceridemic waist: A marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men?. Circulation. 2000; 102: 179–84
   PubMed Web of Science ®Google Scholar
• Lemieux I, Alméras N, Mauriège P, Blanchet C, Dewailly E, Bergeron J, et al. Prevalence of'hypertriglyceridemic waist' in men who participated in the Quebec Health Survey: association with atherogenic and diabetogenic metabolic risk factors. Can J Cardiol. 2002; 18: 725–32
   PubMed Web of Science ®Google Scholar
• Lemieux I, Poirier P, Bergeron J, Alméras N, Lamarche B, Cantin B, et al. Hypertriglyceridemic waist: A useful screening phenotype in preventing cardiology?. Can J Cardiol. 2007; 23 Suppl B: 725–32
   Google Scholar
• Solati M, Ghanbarian A, Rahmani M, Sarbazi N, Allahverdian S, Azizi F. Cardiovascular risk factors in males with hypertriglycemic waist (Tehran Lipid and Glucose Study). Int J Obes Relat Metab Disord. 2004; 28: 706–9
   Google Scholar
• LaMonte MJ, Ainsworth BE, DuBose KD, Grandjean PW, Davis PG, Yanowitz FG, et al. The hypertriglyceridemic waist phenotype among women. Atherosclerosis. 2003; 171: 123–30
   PubMed Web of Science ®Google Scholar
• Czernichow S, Bruckert E, Bertrais S, Galan P, Hercberg S, Oppert JM. Hypertriglyceridemic waist and 7.5-year prospective risk of cardiovascular disease in asymptomatic middle-aged men. Int J Obes (Lond) 2007; 31: 791–6
   PubMed Web of Science ®Google Scholar
• Tanko LB, Bagger YZ, Qin G, Alexandersen P, Larsen PJ, Christiansen C. Enlarged waist combined with elevated triglycerides is a strong predictor of accelerated atherogenesis and related cardiovascular mortality in postmenopausal women. Circulation. 2005; 111: 1883–90
   PubMed Web of Science ®Google Scholar
• Arsenault BJ. Hypertriglyceridemic waist predicts coronary heart disease in the EPIC-Norfolk Prospective Population Study. Diabetologia Abstract Volume 43th Annual Meeting. 2007;50 Suppl 1:S10 abstract 0008.
   Google Scholar
• Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA. 2007; 297: 611–9
   PubMed Web of Science ®Google Scholar
• Libby P. Inflammation in atherosclerosis. Nature. 2002; 420: 868–74
   PubMed Web of Science ®Google Scholar
• Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997; 336: 973–9
   PubMed Web of Science ®Google Scholar
• Boekholdt SM, Hack CE, Sandhu MS, Luben R, Bingham SA, Wareham NJ, et al. C-reactive protein levels and coronary artery disease incidence and mortality in apparently healthy men and women: the EPIC-Norfolk prospective population study 1993–2003. Atherosclerosis. 2006; 187: 415–22
   PubMed Web of Science ®Google Scholar
• Kang ES, Kim HJ, Ahn CW, Park CW, Cha BS, Lim SK, et al. Relationship of serum high sensitivity C-reactive protein to metabolic syndrome and microvascular complications in type 2 diabetes. Diabetes Res Clin Pract. 2005; 69: 151–9
   PubMedGoogle Scholar
• Lemieux I, Pascot A, Prud'homme D, Alméras N, Bogaty P, Nadeau A, et al. Elevated C-reactive protein: another component of the atherothrombotic profile of abdominal obesity. Arterioscler Thromb Vasc Biol. 2001; 21: 961–7
   PubMed Web of Science ®Google Scholar
• Arnaud C, Burger F, Steffens S, Veillard NR, Nguyen TH, Trono D, et al. Statins reduce interleukin-6-induced C-reactive protein in human hepatocytes: new evidence for direct antiinflammatory effects of statins. Arterioscler Thromb Vasc Biol. 2005; 25: 1231–6
   PubMed Web of Science ®Google Scholar
• Bataille R, Klein B. C-reactive protein levels as a direct indicator of interleukin-6 levels in humans in vivo. Arthritis Rheum. 1992; 35: 982–4
   Google Scholar
• Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998; 339: 229–34
   PubMed Web of Science ®Google Scholar
• Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA. 1979; 241: 2035–8
   PubMed Web of Science ®Google Scholar
• Stevens RJ, Kothari V, Adler AI, Stratton IM. The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clin Sci (Lond) 2001; 101: 671–9
   PubMed Web of Science ®Google Scholar
• Alexander CM, Landsman PB, Teutsch SM, Haffner SM. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes. 2003; 52: 1210–4
   PubMed Web of Science ®Google Scholar
• Bonora E, Targher G, Formentini G, Calcaterra F, Lombardi S, Marini F, et al. The Metabolic Syndrome is an independent predictor of cardiovascular disease in Type 2 diabetic subjects. Prospective data from the Verona Diabetes Complications Study. Diabet Med. 2004; 21: 52–8
   PubMed Web of Science ®Google Scholar
• Albu J, Konnarides C, Pi-Sunyer FX. Weight control: Metabolic and cardiovascular effects. Diabetes Rev. 1995; 3: 335–47
   Google Scholar
• Williams G. Obesity and type 2 diabetes: a conflict of interests?. Int J Obes Relat Metab Disord. 1999; 23 Suppl 7: S2–4
   Google Scholar
• Williamson DF, Thompson TJ, Thun M, Flanders D, Pamuk E, Byers T. Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care. 2000; 23: 1499–504
   PubMed Web of Science ®Google Scholar
• Leibson CL, Williamson DF, Melton LJ 3rd, Palumbo PJ, Smith SA, Ransom JE, et al. Temporal trends in BMI among adults with diabetes. Diabetes Care. 2001; 24: 1584–9
   PubMed Web of Science ®Google Scholar
• Pi-Sunyer X, Blackburn G, Brancati FL, Bray GA, Bright R, Clark JM, et al. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care. 2007; 30: 1374–83
   PubMed Web of Science ®Google Scholar
• Kissebah AH, Freedman DS, Peiris AN. Health risks of obesity. Med Clin North Am. 1989; 73: 111–38
   PubMed Web of Science ®Google Scholar
• Després JP, Lemieux I, Prud'homme D. Treatment of obesity: need to focus on high risk abdominally obese patients. BMJ. 2001; 322: 716–20
   PubMed Web of Science ®Google Scholar
• Grundy SM, Pasternak R, Greenland P, Smith S, Jr, Fuster V. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation. 1999; 100: 1481–92
   PubMed Web of Science ®Google Scholar
• Balkau B, Shipley M, Jarrett RJ, Pyorala K, Pyorala M, Forhan A, et al. High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study. Diabetes Care. 1998; 21: 360–7
   PubMed Web of Science ®Google Scholar
• St-Pierre J, Lemieux I, Vohl MC, Perron P, Tremblay G, Després JP, et al. Contribution of abdominal obesity and hypertriglyceridemia to impaired fasting glucose and coronary artery disease. Am J Cardiol. 2002; 90: 15–8
   Google Scholar
• Després JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature. 2006; 444: 881–7
   PubMed Web of Science ®Google Scholar
• Dagenais GR, Yi Q, Mann JF, Bosch J, Pogue J, Yusuf S. Prognostic impact of body weight and abdominal obesity in women and men with cardiovascular disease. Am Heart J. 2005; 149: 54–60
   PubMed Web of Science ®Google Scholar
• Rexrode KM, Carey VJ, Hennekens CH, Walters EE, Colditz GA, Stampfer MJ, et al. Abdominal adiposity and coronary heart disease in women. JAMA. 1998; 280: 1843–8
   PubMed Web of Science ®Google Scholar
• Lapidus L, Bengtsson C, Larsson B, Pennert K, Rybo E, Sjostrom L. Distribution of adipose tissue and risk of cardiovascular disease and death: a 12 year follow up of participants in the population study of women in Gothenburg, Sweden. Br Med J (Clin Res Ed) 1984; 289: 1257–61
   PubMed Web of Science ®Google Scholar
• Folsom AR, Stevens J, Schreiner PJ, McGovern PG. Body mass index, waist/hip ratio, and coronary heart disease incidence in African Americans and whites. Atherosclerosis Risk in Communities Study Investigators. Am J Epidemiol. 1998; 148: 1187–94
   PubMed Web of Science ®Google Scholar
• Reaven GM. The metabolic syndrome: is this diagnosis necessary?. Am J Clin Nutr. 2006; 83: 1237–47
   PubMed Web of Science ®Google Scholar
• Balkau B, Deanfield JE, Després JP, Bassand JP, Fox KA, Smith SC, Jr, et al. International Day for the Evaluation of Abdominal Obesity (IDEA): a study of waist circumference, cardiovascular disease, and diabetes mellitus in 168,000 primary care patients in 63 countries. Circulation. 2007; 116: 1942–51
   PubMed Web of Science ®Google Scholar
• Ferland M, Després JP, Tremblay A, Pinault S, Nadeau A, Moorjani S, et al. Assessment of adipose tissue distribution by computed axial tomography in obese women: association with body density and anthropometric measurements. Br J Nutr. 1989; 61: 139–148
   PubMed Web of Science ®Google Scholar
• Lemieux I, Drapeau V, Richard D, Bergeron J, Marceau P, Biron S, et al. Waist girth does not predict metabolic complications in severely obese men. Diabetes Care. 2006; 29: 1417–9
   PubMed Web of Science ®Google Scholar
• Blackburn P, Lemieux I, Lamarche B, Bergeron J, Perron P, Tremblay G, et al. Type 2 diabetes without the atherogenic metabolic triad does not predict angiographically-assessed coronary artery disease in women. Diabetes Care. 2008; 31: 170–2
   Google Scholar
• Smith SC, Jr, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation. 2006; 113: 2363–72
   PubMed Web of Science ®Google Scholar
• Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998; 97: 1837–47
   PubMed Web of Science ®Google Scholar
• Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation. 2002; 105: 310–5
   PubMed Web of Science ®Google Scholar
• Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, et al. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil. 2007; 14 Suppl 2: S1–113
   PubMed Web of Science ®Google Scholar
• IDF Clinical Guidelines Task Force. Global Guideline for Type 2 Diabetes: recommendations for standard, comprehensive, and minimal care. Diabet Med. 2006; 23: 579–93
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jr, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003; 42: 1206–52
   PubMed Web of Science ®Google Scholar
• Ross R, Dagnone D, Jones PJ, Smith H, Paddags A, Hudson R, et al. Reduction in obesity and related comorbid conditions after diet-induced weight loss or exercise-induced weight loss in men. A randomized, controlled trial. Ann Intern Med. 2000; 133: 92–103
   PubMed Web of Science ®Google Scholar
• Orchard TJ, Temprosa M, Goldberg R, Haffner S, Ratner R, Marcovina S, et al. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med. 2005; 142: 611–9
   PubMed Web of Science ®Google Scholar
• Katzmarzyk PT, Leon AS, Wilmore JH, Skinner JS, Rao DC, Rankinen T, et al. Targeting the metabolic syndrome with exercise: evidence from the HERITAGE Family Study. Med Sci Sports Exerc. 2003; 35: 1703–9
   PubMed Web of Science ®Google Scholar
• Dumont M, Mauriège P, Bergeron J, Després JP, Prud'homme D. Effect of a six month gemfibrozil treatment and dietary recommendations on the metabolic risk profile of visceral obese men. Int J Obes Relat Metab Disord. 2001; 25: 1136–43
   Google Scholar
• Leon AS, Sanchez OA. Response of blood lipids to exercise training alone or combined with dietary intervention. Med Sci Sports Exerc. 2001;33 Suppl:S502–15; discussion S528–9.
   Google Scholar
• Bluher M, Engeli S, Kloting N, Berndt J, Fasshauer M, Batkai S, et al. Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes. 2006; 55: 3053–60
   PubMed Web of Science ®Google Scholar
• Côté M, Matias I, Lemieux I, Petrosino S, Alméras N, Després JP, et al. Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men. Int J Obes (Lond) 2007; 31: 692–9
   PubMed Web of Science ®Google Scholar
• Després JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med. 2005; 353: 2121–34
   PubMed Web of Science ®Google Scholar